Subscribe to RoboticOncology.com RSS Feed

MRI-Guided Prostate Biopsy Improves Accuracy and Patient Comfort

NEW YORK, NY--(Marketwired - Apr 7, 2014) - During trial, a new MRI-guided prostate biopsy yielded more targeted prostate tissue retrieval and improved diagnosis accuracy. The combined multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR) guided biopsy (MRGB) techniques reduced the incidence of low-risk prostate cancer diagnosis and improved overall detection of intermediate- to high-risk disease compared to the traditional biopsy method.

Currently, transrectal ultrasound is used to guide the collection of as many as
30 random prostate tissue samples. In contrast, the two-part biopsy uses mpMRI to visually assess the prostate and then, if necessary, MRGB to collect just two needle samples from the tumor-identified area. Leading robotic prostate surgeon, David B. Samadi, MD, believes the new test will improve the patient experience and, more importantly, prostate cancer diagnosis and treatment planning.

"The MRI biopsy gives us the opportunity for very targeted tissue sampling, a more comfortable patient, and more accurate results," said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital.

Based on findings from the Australian clinical trial, researchers believe the mpMRI will better serve men with prostate cancer by increasing the detection of intermediate-risk and high-risk disease. At the same time, men as a whole will benefit from a reduction in over testing and over diagnosis of low-risk, indolent cancer.

From July 2012 through January 2013, a total of 223 men with elevated prostate-specific antigen (PSA) levels participated in the biopsy study. All patients received the mpMRI biopsy and the traditional ultrasound-guided biopsy.

Findings showed three main benefits of mpMRI/MRGB over ultrasound biopsy:

  • 51 percent reduction in patient need for prostate biopsy
  • 89.4 percent reduction in low-risk prostate cancer diagnosis
  • 17.7 percent increased detection of intermediate/high-risk prostate cancer

"While overtreatment of prostate cancer is not ideal, the new test will require us to remain vigilant -- not all low-risk diagnoses can be ignored," said Dr. Samadi. "Patients must work closely with prostate cancer experts to determine the best course of treatment. Individual assessment of risk factors will continue to play a role in the decision about whether or not to undergo treatment, even for those with low-risk diagnosis."

Back to Press Releases


Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:

1-212-365-5000

Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.




Testimonials
S. Davis, USA

Dr. Samadi’s team from check-in to check-out was superlative.  And Dr. Samadi’s record of personally conducted robotic procedures and success rates are beyond compare.

more..
Jose M. C., Colombia

Siempre recordare el 2009 como el mas tragico de mi vida ; sin presentar sintomas y a raiz de mi examen anual de salud me fue detectado un cancer de prostata, la intuicion de mi medico personal al ver mi psa en 3.4 lo hizo referirme al urologo para que me practicase una biopsia , el mundo se me vino encima.

more..
William and Glenn, USA

In May of 2010 my brother Glenn was suffering from back pain. After tests for kidney stones were negative it was discovered that his PSA level was 9.

more..
Len F.

On Oct. 1, 2009, I was diagnosed with prostate cancer.  I had anticipated that the biopsy findings would be negative and I was rather shocked with this diagnosis.

more..